Skip to main content

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.

The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com
617.599.8178


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.70
+0.00 (0.00%)
AAPL  270.71
+0.00 (0.00%)
AMD  323.21
+0.00 (0.00%)
BAC  52.66
+0.00 (0.00%)
GOOG  347.50
+0.00 (0.00%)
META  671.34
-0.00 (-0.00%)
MSFT  429.25
+0.00 (0.00%)
NVDA  213.17
+0.00 (0.00%)
ORCL  165.96
+0.00 (0.00%)
TSLA  376.02
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.